Stock Analysis: Tonghua Dongbao Pharmaceutical

Company: Tonghua Dongbao Pharmaceutical Company Limited

Bloomberg ticker: 600867 SH

Market cap: US$13,832m

Background: Tonghua Dongbao Pharmaceutical Company Limited is a major Chinese drug manufacturer specializing in diabetes treatments. It produces high-quality insulin products for domestic and international markets. A key milestone in its global expansion is its strategic insulin supply partnership with the French healthcare giant Sanofi.

World Class Benchmarking of Tonghua Dongbao Pharmaceutical

• Profitable Growth rank of 1 was up compared to the prior period’s 8th rank

• This is World Class performance compared to 310 medium Health Care companies worldwide

• Profitability rank of 1 was the same as its Growth rank of 1

• Profitability rank of 1 was up compared to the prior period’s 8th rank

• This is World Class performance compared to peers

• Growth rank of 1 was up compared to the prior period’s 10th rank

• This is World Class performance compared to peers